New Japanese encephalitis vaccines: alternatives to production in mouse brain

References

• Halstead S, Jacobson J. Japanese encephalitis vaccines In: Vaccines. Plotkin SA, Orenstein WA, Offit PA (Eds). Elsevier, PA, USA, 311–352 (2008).
   Google Scholar
• Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg. Infect. Dis.15(1), 1–7 (2009).
   PubMed Web of Science ®Google Scholar
• Fischer M, Lindsey N, Staples JE, Hills S. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.59(RR-1), 1–27 (2010).
   PubMedGoogle Scholar
• Solomon T. Flavivirus encephalitis. N. Engl. J. Med.351(4), 370–378 (2004).
   PubMed Web of Science ®Google Scholar
• Wittesjo B, Eitrem R, Niklasson B, Vene S, Mangiafico JA. Japanese encephalitis after a 10-day holiday in Bali. Lancet345(8953), 856–857 (1995).
   PubMed Web of Science ®Google Scholar
• Caramello P, Canta F, Balbiano R et al. A case of imported JE acquired during short travel in Vietnam. Are current recommendations about vaccination broader? J. Travel Med.14(5), 346–348 (2007).
   PubMed Web of Science ®Google Scholar
• Halstead SB, Grosz CR. Subclinical Japanese encephalitis. I. Infection of Americans with limited residence in Korea. Am. J. Hyg.75, 190–201 (1962).
   PubMedGoogle Scholar
• Benenson MW, Top FH Jr, Gresso W, Ames CW, Altstatt LB. The virulence to man of Japanese encephalitis virus in Thailand. Am. J. Trop. Med. Hyg.24(6 Pt 1), 974–980 (1975).
   PubMedGoogle Scholar
• Gajanana A, Thenmozhi V, Samuel PP, Reuben R. A community-based study of subclinical flavivirus infections in children in an area of Tamil Nadu, India, where Japanese encephalitis is endemic. Bull. World Health Organ.73(2), 237–244 (1995).
   PubMed Web of Science ®Google Scholar
• Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.42(RR-1), 1–15 (1993).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Japanese encephalitis among three U.S. travelers returning from Asia, 2003–2008. MMWR Morb. Mortal. Wkly Rep.58(27), 737–740 (2009).
   PubMedGoogle Scholar
• Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973–2008. Am. J. Trop. Med. Hyg.82(5), 930–936 (2010).
   PubMed Web of Science ®Google Scholar
• Macdonald WB, Tink AR, Ouvrier RA et al. Japanese encephalitis after a two-week holiday in Bali. Med. J. Aust.150(6), 334–336, 339 (1989).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Japanese encephalitis in a U.S. traveler returning from Thailand, 2004. MMWR Morb. Mortal. Wkly Rep.54(5), 123–125 (2005).
   PubMedGoogle Scholar
• Rose MR, Hughes SM, Gatus BJ. A case of Japanese B encephalitis imported into the United Kingdom. J. Infect.6(3), 261–265 (1983).
   PubMedGoogle Scholar
• Burdon JT, Stanley PJ, Lloyd G, Jones NC. A case of Japanese encephalitis. J. Infect.28(2), 175–179 (1994).
   PubMedGoogle Scholar
• Buhl MR, Black FT, Andersen PL, Laursen A. Fatal Japanese encephalitis in a Danish tourist visiting Bali for 12 days. Scand. J. Infect. Dis.28(2), 189 (1996).
   PubMed Web of Science ®Google Scholar
• Buhl MR, Lindquist L. Japanese encephalitis in travelers: review of cases and seasonal risk. J. Travel Med.16(3), 217–219 (2009).
   PubMed Web of Science ®Google Scholar
• Saito M, Sunagawa T, Makino Y et al. Three Japanese encephalitis cases in Okinawa, Japan, 1991. Southeast Asian J. Trop. Med. Public Health30(2), 277–279 (1999).
   PubMedGoogle Scholar
• Monnet FP. Behavioural disturbances following Japanese B encephalitis. Eur. Psychiatry18(6), 269–273 (2003).
   PubMedGoogle Scholar
• Geraghty CM, McCarthy JS. Japanese encephalitis vaccine: is it being sufficiently used in travellers? Med. J. Aust.181(5), 269–270 (2004).
   PubMedGoogle Scholar
• Hanson JP, Taylor CT, Richards AR, Smith IL, Boutlis CS. Japanese encephalitis acquired near Port Moresby: implications for residents and travellers to Papua New Guinea. Med. J. Aust.181(5), 282–283 (2004).
   PubMedGoogle Scholar
• Ostlund MR, Kan B, Karlsson M, Vene S. Japanese encephalitis in a Swedish tourist after travelling to Java and Bali. Scand. J. Infect. Dis.36(6–7), 512–513 (2004).
   PubMedGoogle Scholar
• Cutfield NJ, Anderson NE, Brickell K, Hueston L, Pikholz C, Roxburgh RH. Japanese encephalitis acquired during travel in China. Intern. Med. J.35(8), 497–498 (2005).
   PubMedGoogle Scholar
• Lehtinen VA, Huhtamo E, Siikamaki H, Vapalahti O. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J. Clin. Virol.43(1), 93–95 (2008).
   PubMed Web of Science ®Google Scholar
• Poland JD, Cropp CB, Craven RB, Monath TP. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J. Infect. Dis.161(5), 878–882 (1990).
   PubMed Web of Science ®Google Scholar
• Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr. Top. Microbiol. Immunol.267, 171–194 (2002).
   PubMed Web of Science ®Google Scholar
• Vaughn D, Barrett A, Solomon T. Flaviviruses (yellow fever, dengue, dengue hemorrhagic fever, Japanese encephalitis, West Nile, St. Louis encephalitis, tick-borne encephalitis). In: Principals and Practice of Infectious Diseases. Mandell GL, Bennett JE, Dolin R (Eds). Elsevier, Philadelphia, PA, USA, 2133–2156 (2009).
   Google Scholar
• Solomon T, Dung NM, Kneen R et al. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain125(Pt 5), 1084–1093 (2002).
   PubMed Web of Science ®Google Scholar
• Dickerson RB, Newton JR, Hansen JE. Diagnosis and immediate prognosis of Japanese B encephalitis; observations based on more than 200 patients with detailed analysis of 65 serologically confirmed cases. Am. J. Med.12(3), 277–288 (1952).
   PubMedGoogle Scholar
• Kimura K, Dosaka A, Hashimoto Y, Yasunaga T, Uchino M, Ando M. Single-photon emission CT findings in acute Japanese encephalitis. AJNR Am. J. Neuroradiol.18(3), 465–469 (1997).
   PubMedGoogle Scholar
• Misra UK, Kalita J, Jain SK, Mathur A. Radiological and neurophysiological changes in Japanese encephalitis. J. Neurol. Neurosurg. Psychiatr.57(12), 1484–1487 (1994).
   PubMedGoogle Scholar
• Kumar R, Mathur A, Singh KB et al. Clinical sequelae of Japanese encephalitis in children. Indian J. Med. Res.97, 9–13 (1993).
   PubMed Web of Science ®Google Scholar
• Solomon T, Dung NM, Wills B et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet361(9360), 821–826 (2003).
   PubMed Web of Science ®Google Scholar
• Harinasuta C, Nimmanitya S, Titsyakorn U. The effect of interferon-alpha A on two cases of Japanese encephalitis in Thailand. Southeast Asian J. Trop. Med. Public Health16(2), 332–336 (1985).
   PubMedGoogle Scholar
• Kumar R, Tripathi P, Baranwal M, Singh S, Tripathi S, Banerjee G. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin. Infect. Dis.48(4), 400–406 (2009).
   PubMed Web of Science ®Google Scholar
• Hammon WM, Tigertt WD, Sather GE, Berge TO, Meiklejohn G. Epidemiologic studies of concurrent virgin epidemics of Japanese B encephalitis and of mumps on Guam, 1947–1948, with subsequent observations including dengue, through 1957. Am. J. Trop. Med. Hyg.7(4), 441–467 (1958).
   PubMedGoogle Scholar
• Libraty DH, Nisalak A, Endy TP, Suntayakorn S, Vaughn DW, Innis BL. Clinical and immunological risk factors for severe disease in Japanese encephalitis. Trans. R. Soc. Trop. Med. Hyg.96(2), 173–178 (2002).
   PubMedGoogle Scholar
• Luo D, Yao R, Song J, Huo H, Wang Z. The effect of DDT spraying and bed nets impregnated with pyrethroid insecticide on the incidence of Japanese encephalitis virus infection. Trans. R. Soc. Trop. Med. Hyg.88(6), 629–631 (1994).
   PubMedGoogle Scholar
• Luo D, Zhang K, Song J et al. The protective effect of bed nets impregnated with pyrethroid insecticide and vaccination against Japanese encephalitis. Trans. R. Soc. Trop. Med. Hyg.88(6), 632–634 (1994).
   PubMedGoogle Scholar
• Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine18(Suppl. 2), 26–32 (2000).
   PubMed Web of Science ®Google Scholar
• Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine23(45), 5205–5211 (2005).
   PubMed Web of Science ®Google Scholar
• Paulke-Korinek M, Kollaritsch H. Japanese encephalitis and vaccines: past and future prospects. Wien. Klin. Wochenschr.120(19–20 Suppl. 4), 15–19 (2008).
   PubMedGoogle Scholar
• Schioler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst. Rev. (3), CD004263 (2007).
   PubMedGoogle Scholar
• Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev. Vaccines7(5), 689–693 (2008).
   PubMed Web of Science ®Google Scholar
• Global Advisory Committee on Vaccine Safety, 9–10 June 2005. Wkly Epidemiol. Rec.80(28), 242–247 (2005).
   PubMedGoogle Scholar
• Hoke CH, Nisalak A, Sangawhipa N et al. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med.319(10), 608–614 (1988)
   PubMed Web of Science ®Google Scholar
• Beasley DW, Lewthwaite P, Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin. Biol. Ther.8(1), 95–106 (2008).
   PubMed Web of Science ®Google Scholar
• Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet337(8748), 1044 (1991).
   PubMed Web of Science ®Google Scholar
• Ruff TA, Eisen D, Fuller A, Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet338(8771), 881–882 (1991).
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Konishi E. Combating Japanese encephalitis: Vero-cell derived inactivated vaccines and the situation in Japan. Future Virol.5(6), 785–799 (2010).
   Web of Science ®Google Scholar
• Srivastava AK, Putnak JR, Lee SH et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine19(31), 4557–4565 (2001).
   PubMed Web of Science ®Google Scholar
• Bista MB, Banerjee MK, Shin SH et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet358(9284), 791–795 (2001).
   PubMed Web of Science ®Google Scholar
• Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case–control study. Lancet366(9494), 1375–1378 (2005).
   PubMed Web of Science ®Google Scholar
• Tandan JB, Ohrr H, Sohn YM et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case–control study in Nepalese children 5 years after immunization. Vaccine25(27), 5041–5045 (2007).
   PubMed Web of Science ®Google Scholar
• Kumar R, Tripathi P, Rizvi A. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N. Engl. J. Med.360(14), 1465–1466 (2009).
   PubMed Web of Science ®Google Scholar
• Gatchalian S, Yao Y, Zhou B et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine26(18), 2234–2241 (2008).
   PubMed Web of Science ®Google Scholar
• Solomon T. Control of Japanese encephalitis–within our grasp? N. Engl. J. Med.355(9), 869–871 (2006).
   PubMed Web of Science ®Google Scholar
• Yu Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine28(21), 3635–3641 (2010).
   PubMed Web of Science ®Google Scholar
• Abe M, Shiosaki K, Hammar L et al. Immunological equivalence between mouse brain-derived and Vero cell-derived Japanese encephalitis vaccines. Virus Res.121(2), 152–160 (2006).
   PubMed Web of Science ®Google Scholar
• Kuzuhara S, Nakamura H, Hayashida K et al. Non-clinical and Phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine21(31), 4519–4526 (2003).
   PubMed Web of Science ®Google Scholar
• Sugawara K, Nishiyama K, Ishikawa Y et al. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals30(4), 303–314 (2002).
   PubMed Web of Science ®Google Scholar
• Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin. Biol. Ther.9(7), 921–931 (2009).
   PubMed Web of Science ®Google Scholar
• Eckels KH, Yu YX, Dubois DR, Marchette NJ, Trent DW, Johnson AJ. Japanese encephalitis virus live-attenuated vaccine Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine6(6), 513–518 (1988).
   PubMed Web of Science ®Google Scholar
• Montagnon BJ. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev. Biol. Stand.70, 27–47 (1989).
   PubMedGoogle Scholar
• Lyons A, Kanesa-thasan N, Kuschner RA et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine25(17), 3445–3453 (2007).
   PubMed Web of Science ®Google Scholar
• Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomised controlled trial. Lancet370(9602), 1847–1853 (2007).
   PubMed Web of Science ®Google Scholar
• Tauber E, Kollaritsch H, von Sonnenburg F et al. Randomized, double-blind, placebo-controlled Phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J. Infect. Dis.198(4), 493–499 (2008).
   PubMed Web of Science ®Google Scholar
• Schuller E, Jilma B, Voicu V et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 six and 12 month results of a multicenter follow-up Phase 3 study. Vaccine26(34), 4382–4386 (2008).
   PubMed Web of Science ®Google Scholar
• Schuller E, Klade CS, Wolfl G, Kaltenbock A, Dewasthaly S, Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine27(15), 2188–2193 (2009).
   PubMed Web of Science ®Google Scholar
• Dubischar-Kastner K, Kaltenboeck A, Klingler A, Jilma B, Schuller E. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine IXIARO (IC51), in 6 months of follow-up. Vaccine28(39), 6463–6469 (2010).
   PubMed Web of Science ®Google Scholar
• Schuller E, Klade CS, Heinz FX et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine26(48), 6151–6156 (2008).
   PubMed Web of Science ®Google Scholar
• Kaltenbock A, Dubischar-Kastner K, Eder G et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine Havrix1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine27(33), 4483–4489 (2009).
   PubMed Web of Science ®Google Scholar
• Dubischar-Kastner K, Eder S, Buerger V et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine28(32), 5197–5202 (2010).
   PubMed Web of Science ®Google Scholar
• Kaltenbock A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine28(3), 834–839 (2010).
   PubMed Web of Science ®Google Scholar
• Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol.73(4), 3095–3101 (1999).
   PubMed Web of Science ®Google Scholar
• Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine28(3), 632–649 (2010).
   PubMed Web of Science ®Google Scholar
• Monath TP, Soike K, Levenbook I et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine17(15–16), 1869–1882 (1999).
   PubMed Web of Science ®Google Scholar
• Bhatt TR, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am. J. Trop. Med. Hyg.62(4), 480–484 (2000).
   PubMed Web of Science ®Google Scholar
• Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine20(7–8), 1004–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Monath TP, Guirakhoo F, Nichols R et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis.188(8), 1213–1230 (2003).
   PubMed Web of Science ®Google Scholar
• Torresi J, McCarthy K, Feroldi E, Meric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled Phase 3 trials. Vaccine28(50), 7993–8000 (2010).
   PubMed Web of Science ®Google Scholar
• Chokephaibulkit K, Sirivichayakul C, Thisyakorn U et al. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr. Infect. Dis. J.29(12), 1111–1117 (2010).
   PubMed Web of Science ®Google Scholar
• Nasveld PE, Marjason J, Bennett S et al. Concomitant or sequential administration of live attenuated japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind Phase II evaluation of safety and immunogenicity. Hum. Vaccin.6(11), 906–914 (2010).
   PubMed Web of Science ®Google Scholar
• Nasveld PE, Ebringer A, Elmes N et al. Long term immunogenicity of live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year Phase II study in healthy adults. Hum. Vaccin.6(10), 1038–1046 (2010).
   PubMed Web of Science ®Google Scholar
• WTO. Yearbook of tourism statistics: data 2000–2004. Nations U (Ed.). World Tourism Organization, Madrid, Spain (2006).
   Google Scholar
• Hatz C, Werlein J, Mutsch M, Hufnagel M, Behrens RH. Japanese encephalitis: defining risk incidence for travelers to endemic countries and vaccine prescribing from the UK and Switzerland. J. Travel Med.16(3), 200–203 (2009).
   PubMed Web of Science ®Google Scholar
• Ding D, Kilgore PE, Clemens JD, Wei L, Zhi-Yi X. Cost–effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. Bull. World Health Organ.81(5), 334–342 (2003).
   PubMed Web of Science ®Google Scholar
• Liu W, Clemens JD, Kari K, Xu ZY. Cost–effectiveness of Japanese encephalitis (JE) immunization in Bali, Indonesia. Vaccine26(35), 4456–4460 (2008).
   PubMed Web of Science ®Google Scholar
• Touch S, Suraratdecha C, Samnang C et al. A cost–effectiveness analysis of Japanese encephalitis vaccine in Cambodia. Vaccine28(29), 4593–4599 (2010).
   PubMed Web of Science ®Google Scholar
• Siraprapasiri T, Sawaddiwudhipong W, Rojanasuphot S. Cost benefit analysis of Japanese encephalitis vaccination program in Thailand. Southeast Asian J. Trop. Med. Public Health28(1), 143–148 (1997).
   PubMedGoogle Scholar